<DOC>
	<DOC>NCT02866331</DOC>
	<brief_summary>This study is performed to reveal the safety and feasibility of combination therapy with autologous cord blood mononuclear cells (CB) and G-CSF as well as repeated administration of G-CSF for children with cerebral palsy. The evaluation tools are as follows: (1) Developmental tests (DDST, PEDI, GMFM, GMFCS, MACS, QUEST), (2) Neurocognitive function test (WPPSI-IV), (3) Brain MRI-DTI, (4) Peripheral blood CD34+ cell counts, (5) Neurotrophic factors/anti-inflammatory cytokines.</brief_summary>
	<brief_title>G-CSF and Autologous Cord Blood Infusion in Cerebral Palsy</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Ages from 2 years to 10 years at the time of enrollment Nonsevere type of cerebral palsy Willing to comply with all study procedures Previous participation within 1 year in a clinical study with stem cell therapy including cord blood, GCSF, and erythropoietin Presence of chromosomal abnormalities Unwillingness to participate clinical trial Presence of hypersensitivity reaction to GCSF Evidence of hepatic, renal, cardiac dysfunctions</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>